EU Researchers Grow Living Bone, Fat and Muscle With a New Bioprinting Method

Living Materials, Printed

Researchers backed by the European Union have developed a 3D bioprinting technique that grows living bone, fat and muscle tissue directly in the lab. The work, reported by Horizon Magazine (the EU's research publication), opens a surprising range of applications — from testing leukaemia drugs to producing cultivated meat.

The PRISM-LT Project

The research is coordinated under PRISM-LT, a five-year EU-funded project running through 2027. At its core is the idea of engineered living materials (ELMs) — structures built from living cells that can grow, adapt, and perform functions traditional materials can't.

'The project aims to deliver a platform that can engineer different tissues serving very different purposes, but using the same principles,' the team explained. That versatility is the headline: one bioprinting platform, multiple tissue types.

Two Very Different Payoffs

Medicine: better drug testing

In the health domain, the focus is on building 3D bone marrow models to study drugs for conditions that affect it — including leukaemia. Lab-grown bone marrow lets researchers test treatments on tissue that behaves like the real thing, potentially speeding up and de-risking early drug development.

Food: cultivated meat with the right texture

On the food side, the same bioprinting approach is being used to engineer the texture of alternative meats. 'Thanks to our bioprinting technology, we can achieve the right texture in alternative meats,' a project researcher noted. That tackles one of cultivated meat's biggest consumer hurdles: mouthfeel.

Why It Matters

Bioprinting has long promised lab-grown organs and tissue, but most demonstrations are narrow and fragile. A single platform that reliably produces bone, fat, and muscle — tissues with very different structures — is a meaningful step toward scalable, functional living materials. The cultivated-meat angle also points to a near-term commercial path that doesn't require the regulatory mountain of implantable human tissue.

The Road Ahead

PRISM-LT runs until 2027, so expect more tissue types and refinement of the platform. For now, the result is a compelling proof point that 'living upgrades' to 3D printing are moving from science fiction toward the lab bench — and maybe, eventually, the dinner plate.